Showing 6621-6630 of 23150 results for "".
The 3 Rs of Facial Plastic Surgery
https://reachmd.com/ma-issues-index/march-april-2026-issue/the-3-rs-of-facial-plastic-surgery/56638/A Q&A with AAFPRS President Anthony Brissett, MD, FACSCMS Response to the COVID-19 Pandemic
https://reachmd.com/programs/perspectives-ama/cms-response-to-the-covid-19-pandemic/11974/In the midst of the COVID-19 pandemic, how is CMS, or the Centers for Medicare and Medicaid Services, providing flexibility for physicians?Top 10 Med Errors & Hazards, Part 1
https://reachmd.com/programs/the-drug-report/top-10-med-errors-hazards-part-1/11280/The Institute for Safe Medication Practices recently published a list of the top 10 med errors and hazards. Here are the top four.The Future of Consumer-Driven Health Care
https://reachmd.com/programs/villanova_health_summit/future-consumer-driven-health-care/8110/Health care today is rapidly becoming more consumer-driven as patients take more active roles in their own wellbeing. How will medicine adapt?New Data From the CONFIDENCE Trial: The Effect of Combination Empagliflozin and Finerenone on UACR and eGFR in CKD and Type 2 Diabetes
https://reachmd.com/clinical-practice/nephrology/new-data-from-the-confidence-trial-the-effect-of-combination-empagliflozin-and-finerenone-on-uacr-and-egfr-in-ckd-and-type-2-diabetes/39959/Stay current with the latest data from the CONFIDENCE trial. Dr. Heerspink explains how recent findings translate into clinical practice in this video brief.Global Burden of Stroke and Myocardial Infarction in Patients at High Risk of First MACE: Insights From the VESALIUS-REAL Study
https://reachmd.com/clinical-practice/cardiology/global-burden-of-stroke-and-myocardial-infarction-in-patients-at-high-risk-of-first-mace-insights-from-the-vesalius-real-study/39990/Examine global rates of stroke and MI in patients at high-risk of first MACE without prior events, as explored in the VESALIUS-REAL burden of disease study.Primary Results of the VESALIUS-CV Trial: Evolocumab in Patients at High Cardiovascular Risk Without Prior MI or Stroke
https://reachmd.com/clinical-practice/cardiology/primary-results-of-the-vesalius-cv-trial-evolocumab-in-patients-at-high-cardiovascular-risk-without-prior-mi-or-stroke/45568/Dr. Erin Bohula reviews VESALIUS-CV trial findings on evolocumab for primary Cardiovascular prevention in patients at high CV risk without prior MI or stroke.VICTOR Trial Results: Regional Variation in Outcomes and Response to Vericiguat in Patients With HFrEF
https://reachmd.com/clinical-practice/cardiology/victor-trial-results-regional-variation-in-outcomes-and-response-to-vericiguat-in-patients-with-hfref/39249/VICTOR Trial Results: Regional Variation in Outcomes and Response to Vericiguat in Patients With HFrEFImplications of the FINE-ONE Trial: How Might Recently Presented Data From the 2025 Kidney Meeting Influence the Current Treatment Paradigm for Type 1 Diabetes and CKD?
https://reachmd.com/clinical-practice/nephrology/implications-of-the-fine-one-trial-how-might-recently-presented-data-from-the-2025-kidney-meeting-influence-the-current-treatment-paradigm-for-type-1-diabetes-and-ckd/39958/Dr. Pratley evaluates recent data from the FINE-ONE trial and explains the relevance of these findings to clinical practice.Cases From the Real World: 64-Year-Old Man With Moderate NPDR
https://reachmd.com/programs/cme/Cases-From-the-Real-World-64-Year-Old-Man-With-Moderate-NPDR/33172/Listen to our faculty as they discuss real-world use of second-generation retina therapies for patients with DME at risk for interruptions in treatment.